Skip to main content

Nuvigil Disease Interactions

There are 5 disease interactions with Nuvigil (armodafinil).

Major

CNS stimulants (applies to Nuvigil) psychiatric disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Depression

The use of CNS stimulants can cause psychotic symptoms, suicidal ideation, and aggression, and can exacerbate symptoms of behavior disturbance and thought disorder; CNS stimulants may induce a manic or mixed episode in patients with bipolar disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders. All patients (particularly those with psychotic or bipolar disorders) should be monitored closely, especially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. Prior to initiating therapy, all patients should be screened for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or family history of suicide, bipolar disease, or depression). If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. Some CNS stimulants are contraindicated in patients with marked agitation or anxiety.

References

  1. "Product Information. Provigil (modafinil)." Cephalon, Inc PROD (2001):
  2. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical PROD (2001):
  3. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals PROD (2001):
  4. "Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation PROD (2001):
  5. "Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham PROD (2001):
  6. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  7. "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn PROD (2001):
  8. "Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim PROD (2001):
  9. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  10. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  11. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  12. "Product Information. Concerta (methylphenidate)." Alza (2002):
  13. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
  14. "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
  15. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
  16. "Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc (2012):
  17. "Product Information. Fintepla (fenfluramine)." Zogenix, Inc (2020):
  18. "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc SUPPL-23 (2023):
  19. "Product Information. Phentermine Hydrochloride (phentermine)." Tagi Pharma Inc (2019):
  20. "Product Information. Desoxyn (methamphetamine)." Recordati Rare Diseases Inc SUPPL-38 (2023):
View all 20 references
Moderate

Armodafinil (applies to Nuvigil) alcoholism

Moderate Potential Hazard, Moderate plausibility.

Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity. Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Moderate

Armodafinil (applies to Nuvigil) cardiovascular dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Valvular Heart Disease

Armodafinil may cause ECG changes, chest pain, or arrhythmia. Armodafinil should be used with caution in patients with cardiovascular complications. Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. It is recommended to monitor heart rate and blood pressure during treatment with armodafinil. Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Moderate

Armodafinil (applies to Nuvigil) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients. The dosage of armodafinil should be reduced in patients with severe hepatic impairment. Close monitoring is recommended.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):
Moderate

Armodafinil (applies to Nuvigil) psychiatric complications

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Depression

Armodafinil may cause adverse psychiatric reactions. Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania. If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil. Close monitoring of psychiatric symptoms is recommended.

References

  1. "Product Information. Nuvigil (armodafinil)." Cephalon Inc (2007):

Nuvigil drug interactions

There are 481 drug interactions with Nuvigil (armodafinil).

Nuvigil alcohol/food interactions

There are 2 alcohol/food interactions with Nuvigil (armodafinil).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.